India is called the pharmacy of the world for good reason: Indian companies supply roughly a third of America’s generic drugs by volume, dominate global vaccine production, and make medicines affordable for millions across Africa, Asia and Latin America. The generic pharma industry – worth tens of billions of dollars in exports – runs on a precise legal and scientific machinery: patents expire, Indian chemists reverse-engineer the drug, regulators approve the copy, and the price collapses. Here is how that machinery works, from patent cliff to your pharmacy shelf, and why Indian companies dominate it.

Patents and the cliff: where generics begin

A new drug enjoys patent protection – typically 20 years – during which only the innovator can sell it, recouping the billion-dollar R&D cost. When the patent expires – the “patent cliff” – generic manufacturers can legally produce the same medicine. The first generic filer in the US gets 180 days of exclusivity, a lucrative prize that sparks races to the patent office. India’s own patent law adds a twist: Section 3(d) prevents “evergreening” – minor tweaks to extend patents – which is why the cancer drug Glivec’s patent was famously denied in India, keeping cheap generics available. Patent challenges and settlements between innovators and generic firms are a specialised legal battlefield where fortunes turn on court dates.

The ANDA: proving sameness, not inventing

Generic makers do not repeat clinical trials. Instead, they file an Abbreviated New Drug Application (ANDA) with regulators like the US FDA, proving their copy is bioequivalent – absorbed into the bloodstream at the same rate and extent as the original. The active pharmaceutical ingredient (API) is synthesised, often more efficiently than the innovator’s process – Indian process chemistry is world-class – and formulated into tablets or injectables. Manufacturing must meet current Good Manufacturing Practices (cGMP); US FDA inspections of Indian plants are rigorous and frequent, and warning letters or import alerts for quality lapses have hit several large Indian companies, denting revenues and reputations. Quality compliance is the industry’s permanent tax: the cost advantage means nothing if the FDA bars your plant.

The economics: why generics are 80-90 per cent cheaper

Generic prices collapse because competition replaces monopoly: the first generic might price at 60 per cent of the brand, but with five or ten competitors, prices fall to 10 to 20 per cent of the original. Indian companies win this game through low manufacturing costs, process innovation and scale – producing billions of tablets across hundreds of ANDAs. The business has two tiers: the high-margin US market, where a single successful generic launch can add hundreds of crores in profit, and the volume-driven emerging markets and domestic business. Portfolio strategy is everything: companies chase “complex generics” – inhalers, injectables, biosimilars – where fewer competitors mean durable margins, while plain oral tablets face brutal price erosion of 5 to 10 per cent annually.

From factory to pharmacy: the supply chain

• API manufacturers (often separate companies) synthesise the active ingredient; formulation plants turn it into finished doses.
• Regulatory approvals: US FDA, European EMA and India’s CDSCO each clear products for their markets.
• Distributors and wholesalers move stock to pharmacies; in the US, three wholesalers control most distribution.
• Pharmacy benefit managers and insurers decide formulary placement – which generic gets dispensed – wielding enormous pricing power.
• In India, the chemist’s shelf reflects MRP-controlled pricing under the drug price control order for essential medicines.

The next frontier is biosimilars – generic versions of complex biologic drugs – where Indian companies are investing heavily. If small-molecule generics made India the world’s pharmacy, biosimilars could keep it there for the next twenty years.

FAQs

Are generic drugs as effective as branded ones?

Yes – regulators require bioequivalence, meaning the same active ingredient, strength and absorption. Inactive ingredients may differ, which occasionally affects tolerability but not efficacy.

What is an API?

The Active Pharmaceutical Ingredient – the chemical that actually treats the disease. India is a major API producer, though it still imports many from China.

Why did some Indian plants get US FDA warnings?

Data integrity and manufacturing quality lapses found during inspections. Remediation is expensive and slow, and import alerts block the plant’s products from the US market.

Compiled by the Khabar 24h Editorial Desk from publicly available sources.